
Prescient
Therapeutics
Progress.
Positioning.
Annual General Meeting
November 2022

DISCLAIMER AND SAFE HARBOR

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this presentation. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

The contents of this document are confidential information of Prescient. These contents are made available on a 'for your eyes only' basis to the person to whom it was sent by Prescient. The purpose of the disclosure is to facilitate commercial and confidential discussions between the disclosee and Prescient. It should not be forwarded without without the prior written consent of the Company.

Innovative pipeline in personalised medicine

Prescient Therapeutics

Platform	Program	Screening	Preclinical	Phase IB	Phase II
CAR - T	OmniCAR	AML	CD33; CLL-1		
			Novel TCR binder (THE UNIVERSITY OF TEXAS MD Anderson Cancer Center)		
		Her2+ solid tumours	Her2		
		GBM	Her2; EGFRviii		
		Platform extensions	Various		
	CellPryme	CellPryme-M	Cell manufacturing enhancement		
		CellPryme-A	Adjuvant for cell therapy		
TARGETED THERAPIES	PTX-100		TCL		
	PTX-200		AML		

Key achievements during another productive year

Targeted Therapy Achievements

- ☑ Excellent progress of PTX-100 trial
- ☑ Initiation and enrolment of expansion cohort in TCL
  - Initiation was significantly delayed by logistics bottlenecks in manufacturing and shipping drug, but good enrolment rate has made up ground
- ☑ Demonstrating excellent safety PTX-100
- ☑ Encouraging activity in terms of responses and event free survival

- ☑ Expansion of PTX-200 in AML after 4th complete remission

OmniCAR

Prescient Therapeutics

- ☑ Internal OmniCAR programs (AML; Her2+ solid tumours; GBM) progressing through pre clinical development
- ☑ Technical successes with various aspects of a highly novel platform
- ☑ Strategic collaboration with MD Anderson Cancer Center
  - Largest cancer centre in US
  - Novel TCR-like binder from proprietary leukemia database
- ☑ OmniCAR platform extensions
  - Non-viral transduction
  - Closed end, automated, scalable manufacturing
- ☑ QGen to manufacture OmniCAR T cells for clinical trial
- ☑ Key OmniCAR patent granted in US
- ☑ Building awareness with industry

Prescient Therapeutics

CellPryme-M

CELL MANUFACTURING ENHANCEMENT

- ☑ Announced in June 2022
- ☑ Produces longer lasting, more “youthful” CAR-T cells
- ☑ Doubles helper T cells
- ☑ Doubles tumour control
- ☑ More chemokine receptors for locating tumours
- ☑ Ready for clinical testing

CellPryme-A

ADJUVANT THERAPY

- ☑ Announced in September 2022
- ☑ Overcomes hostile TME
- ☑ Reduces Tregs
- ☑ Increases expansion of CAR-T cells in vivo
- ☑ Doubles penetration of CAR-T cells into tumours
- ☑ Significant synergy with CellPryme-M
- ☑ Ready for clinical testing

Developed in-house in collaboration with Peter Mac

Market backdrop

Considerable sector headwinds

- Inflation hits tech and biotech companies harder, given its erosive effects on future-valued assets…
  - …but eventually this is counterbalanced by elasticity of demand
- Geopolitical uncertainty further eroded risk appetite
- Generalist (“tourist”) investors that were attracted to the healthcare sector during the pandemic have since exited the sector in droves
- Plethora of early-stage deals in 2020 commensurately resulted in more frequent technical bad news being reported

Source: EPFR; Torreya; Biospace; Financial Times

Global Biotech valuations have stabilised

- Enterprise valuations* (a proxy for technology value) appear to have stabilised
- Distress signal are abating (e.g. number of companies with negative EVs are decreasing)



*EV = Market capitalisation – cash + debt
Source: Torreya

Factors that could see US biotech sector regain traction

- Signs that clean-out from generalist investors has ended (appears to have happened)
- Looking past the worst of inflation fears; stabilising rate movements
- Pressure to cover short positions
- Biotech fund inflows
  - Fund inflows remain very strong for US biotech funds and will need deploying
  - Less redemption activity in the new year
- Industry continues to deliver on technical, regulatory and commercial fronts
- M&A activity

Sources: EPFR; Torreya; Biospace; Financial Times

Prescient Therapeutics

PTX-100

FIRST IN CLASS
RAS PATHWAY INHIBITOR

PTX-100 Phase 1B Summary

- Licensed from Yale University
- Targeting cancers predisposed to Ras & Rho mutations

Phase 1b Expansion cohort in T-cell lymphomas (TCL)

- Excellent safety profile
- Encouraging signal in TCL
  - Reponses
  - Time on therapy

- Granted Orphan Drug Designation by US FDA for Peripheral TCL

Licensed from Yale University

Principal Investigator

Professor H. Miles Prince, AM

Epworth

Now in Expansion Cohort for TCL

- 8 – 12 patients with r/r T cell lymphoma
- Expanding number for CTCL patients in light of responses
- Potential bridge to registration study, although FDA guidelines seem to be changing
- Focussing on sweet spot in an area of considerable unmet need
- Shortest path to market

Case Study

- pralatrexate (Folotyn®)
- Approved for PTCL
  - 5,600 cases/year in US
- US$450,540 per patient, per year

Trial update: continued encouraging responses & time on treatment



- 1 VGPR (ongoing)
- 3 PRs (1 ongoing)
- 2 SDs (both ongoing)
- 2 PD
- 3 withdrawn

PTX-100 dose

- 500 mg/m^2
- 1000 mg/m^2
- 2000 mg/m^2

Prescient Therapeutics

Before



After



PTX-200

NOVEL AKT INHIBITION

Phase 1B trial underway: Acute Myeloid Leukemia

- Building upon encouraging Phase 1 results with PTX-200 (monotherapy)
- PI Professor Jeff Lancet at Moffitt, Key Opinion Leader in AML
- 24 patients with cytarabine held constant at 200-400 mg/m^2 as continuous infusion
  - 4 patients with CR/CRi so far
  - 1 patient with PR
- Currently treating expansion cohort at 45 mg/m^2
- Granted Orphan Drug Designation by US FDA

Principal Investigator

Jeffrey E Lancet, M.D.

MOFFITT CANCER CENTER

CR: COMPLETE REMISSION
CRI: COMPLETE RESPONSE WITH INCOMPLETE HEMATOLOGIC RECOVERY
PR: PARTIAL RESPONSE

Prime positioning in the cell therapy industry

CAR-T is booming



CAR-T sector continues its considerable growth over last 12 months despite headwinds

CAR-T Programs

Clinical Trials

Target Antigens



Prescient Therapeutics proprietary data

Understanding antigen landscape is vital



Heme cancers

- Very crowded in certain indications
- ~65% of research is on 4 antigens

- Prescient has unsurpassed knowledge of the cell therapy landscape by indication & antigen
- Crucial in determining competitive forces & opportunities
- OmniCAR can work with all of them!



Solid cancers

- More even distribution of research across different diseases
- Many more antigen targets, reflecting greater heterogeneity of solid tumours

Platforms to overcome CAR-T's key challenges

Prescient Therapeutics

	Challenge	OmniCAR	CellPryme
Safety / Control	No control post infusion	✓	-
Targeting	Difficulties with targeting, antigen heterogeneity	✓	-
Escape	Difficulties with mutating antigens	✓	-
Production efficiency	Cost prohibitive & slow	✓	-
Exhaustion	Cells run out of steam	✓	✓
Trafficking	Cells cannot find their way	✓	✓
Tumor penetrance	Protective layer around tumor	✓	✓✓
Tumor microenvironment	Suppresses immune cells	✓	✓✓

Safe

Effective

Sustainable

Affordable

Enduring

Strategically positioned in the rapidly moving cell therapy landscape



Prescient's CAR-T platform business model



- Huge market
- "Shovels to CAR-T goldrush"
- Diversified risk
- Highly scalable
- Earlier revenue potential

The End Game: Personalized "Plug & Play" Cell Therapy Ecosystem

Step 4:
Bespoke therapy with post-infusion control



Step 3:
Pair binders with OmniCAR cells (T cells; NK; auto/allo)

Step 2:
Match patient's antigens to corresponding binders

Step 1:
Patient sample to determine individual antigen profile

Top-down analysis is sensible for investors



Oncology*
- 2021: US$ 280bn
- 2029: US$ 536bn (8.2% CAGR)

Cell Therapies (CAR-T)
- >US$37bn by 2028^

Prescient Therapeutics
- Next gen platforms
- Scalable
- Controllable
- Any target; any cell
- “Shovels to goldrush” position
- Top pedigree

*Precedence Research 2021
^GlobalData

Prescient Therapeutics

OmniCAR

Universal, Next Generation CAR-Therapies

OmniCAR: flexible, modular CAR platform

Prescient Therapeutics



Penn
University of Pennsylvania

Associate Professor
Daniel J. Powell, Jr

Professor
Andrew Tsourkas

University of Oxford

OmniCAR: Control Features

Modular and covalent architecture of OmniCAR enables true **post-infusion control** of CAR functionality

Dose Titration



Control activity to **safe and efficacious** levels

On/off switch



Turn therapy on/off/on without killing or re-administering cells
= safety & persistence

Target Re-direction



Re-direct cells from one cancer target to another in vivo

Multi-Antigen Targeting



Target **multiple cancer antigens simultaneously** for thorough cancer killing

OmniCAR is at least as potent as conventional CAR-T

Prescient Therapeutics

Conventional CAR-T (Her2)



OmniCAR (Her2)



Her2+ breast cancer cell line MCF7 was co-cultured with either conventional CAR-T or OmniCAR-T cells **both at 2:1 ratio**

Red = live cancer cells
Green =dead cancer cells

No Loss of Potency with modular approach

OmniCAR cell can be Redirected



1. OmniCAR T cells **pre-armed with EGFRviii binder**

   → Rapid cytotoxicity to EGFRviii+ cells

2. **Add Her2 binder**

   → Rapid switching & cytotoxicity to Her2+ cells

No new cells required

OmniCAR cells viable & armable for weeks



- Unarmed & armed OmniCAR-T cells are viable for weeks
- Can be armed at will
- Results in immediate cytotoxicity

Strategic collaboration with MD Anderson



THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®



- MDACC is the largest cancer centre in US
- Using “plug & play” features of OmniCAR to combine novel TCR-like binder with CD33 & CLL-1 for AML
- Create best-in-class adaptable CAR-Ts for blood cancers
- An unprecedented level of multivalency and control.
- First example of 3rd party binder in the Prescient “app store”

TCR BINDER TARGET IS UNDISCLOSED

Prescient Therapeutics

CellPryme

CELL THERAPY ENHANCEMENTS

The CAR-T process

Prescient Therapeutics



1 Blood is collected from the patient



2 T-Cells are isolated



3 T-Cells are genetically altered to have cancer-recognising receptors (CARs)

CellPryme-M



4 Millions of CAR-T cells are grown

CellPryme-A

5 CAR-T cells are administered to the patient

Prescient Therapeutics

CellPryme-M

Cell manufacturing enhancement

More memory cells required for clinical efficacy

- Clinical efficacy of CAR-T therapy remains dependent on the T cell phenotype
- It is possible to control this during the manufacturing step



CellPryme-M produces CAR-T cell types with ideal characteristics and attributes

Persistence
For longevity of effects and continued tumour control

Immune memory
Central memory T cells typically persist 10-20 years and as long as 75 years

Trafficking
CAR-T cells able to find their way to the tumour

Tumour penetrance
Cells that can penetrate solid tumours

Genomic stability
Cells with enhanced self-renewal due to greater genomic stability

Anti-viral
Cells with potent anti-viral characteristics

Prescient Therapeutics

CellPryme-A

Adjuvant for enhancing cell therapies

CellPryme-A addresses the hostile Tumour Microenvironment (TME)

- TME is the **complex ecosystem** surrounding solid tumours
- Protects and nurtures the cancer
- Acts as a **protective "force field"** that bluntens the effectiveness of cancer therapies



Summary of CellPryme-A effects

Boosts tumour killing by conventional CAR-T cells

Reduces problematic **Treg cells** by 66%

Increases ability of T cells to **penetrate solid tumours**

- **4x ↑** Cytotoxic T cells
- **3x ↑** Helper T cells

Improved survival

Dramatically increases **CAR-T cell expansion** within host

- **2x ↑** CAR-T cell expansion
- **9x↑** Cytotoxic T cells
- **6x ↑** Helper T cells

with CellPryme-M

Synergises with CellPryme-M for **even greater benefits**

CellPryme Complements OmniCAR

Prescient Therapeutics

OmniCAR

- Multi-targeting
- Redirection
- Control & safety
- Any target; any cell



Next generation Cell therapies

CellPryme-M

Process that produces a better <u>cell type</u>

- Persistence
- Trafficking



Current generation cell therapies

CellPryme-A

Adjuvant therapy

- Reduces Tregs
- Primes TME for cell therapy
- Boosts CAR-T cell expansion *in vivo*

Summary

Key building blocks to Prescient's future value

Prescient Therapeutics

1 OmniCAR

- Next generation universal CAR platform
  - AML
  - Her2+ solid tumours
  - GBM
- Clinical trial will be a huge catalyst
- 3rd party opportunities

2 CellPryme

- Enhancing current & next-gen cell therapies
- Manufacturing enhancements
- Adjuvant therapy
- 3rd party opportunities
- Clinic ready

3 Targeted therapies

- PTX-100
  - Exciting opportunity in TCL
  - US Orphan Drug designation
  - Could leap deep into clinical development
- PTX-200 in AML

Major catalysts to work towards next year

Prescient will continue to progress the development of programs across its considerable pipeline. Some notable catalysts to work towards include, but are not limited to:

- Read out on TCL of PTX-100 trial
- Clarification of next steps for PTX-100's clinical development in TCL
  - FDA is currently reviewing accelerated approval processes
- In vivo PoC data of OmniCAR in AML
- Initiation of OmniCAR AML clinical study
- Continue to build awareness of Prescient's programs as they progress, amongst industry, institutions, clinicians and investors
- Leveraging CellPryme and OmniCAR with external parties through collaborations and/or licenses

Investment Thesis Summary

Prescient Therapeutics

4 blue chip oncology assets

- 2 next gen platforms
- PTX-100 & PTX-200 in clinic
- Top pedigree

OmniCAR **PTX-100**

CellPryme **PTX-200**

Superior positioning & model

- Internal products + external partnering
- Shovels to goldrush
- Highly scalable

Huge & growing market

- $280bn industry
- Growing demand
- Cell therapy is the future


Prescient
Therapeutics
Thank you!
ASX code: PTX
www.ptxtherapeutics.com